Insider Buying: DexCom (NASDAQ:DXCM) COO Purchases $1,001,728.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach acquired 18,200 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were acquired at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the transaction, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

DexCom Stock Performance

NASDAQ DXCM traded down $0.16 during trading hours on Monday, reaching $54.84. The company’s stock had a trading volume of 8,862,721 shares, compared to its average volume of 4,532,221. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The business has a 50-day simple moving average of $68.83 and a 200 day simple moving average of $77.61. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The stock has a market cap of $21.39 billion, a PE ratio of 38.08, a PEG ratio of 1.43 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DXCM shares. Piper Sandler set a $75.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Barclays set a $80.00 target price on shares of DexCom and gave the stock an “equal weight” rating in a research report on Monday, November 3rd. Citigroup cut their price target on DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Finally, Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the stock a “buy” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.62.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently bought and sold shares of the business. SWS Partners purchased a new position in shares of DexCom during the second quarter valued at $1,661,000. Baader Bank Aktiengesellschaft acquired a new stake in DexCom during the 2nd quarter worth about $393,000. Jennison Associates LLC boosted its position in DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares during the period. Mn Services Vermogensbeheer B.V. grew its stake in DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after acquiring an additional 6,800 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of DexCom by 85.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after purchasing an additional 557,576 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.